{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.","id":"OG000","title":"Group 1 (Avelumab and MHC Class I Up-regulation)"}],"populationDescription":"No patients in Arm I relapsed, so overall number of participants analyzed is 0","reportingStatus":"POSTED","timeFrame":"At 1 year post-transplant","title":"Efficacy, in Terms of Relapse Rate (Arm I)","type":"PRIMARY"}